Patents Assigned to Your Energy Systems, LLC
-
Patent number: 9913801Abstract: The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on Klebsiella pneumonia cultures in vitro, and in vivo as demonstrated by efficacy in reducing by large multiples the presence of cultures of Klebsiella in rats in animal tests. Further, because the liposomal glutathione bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more resistant strains to antibiotic treatment is downgraded.Type: GrantFiled: March 15, 2013Date of Patent: March 13, 2018Assignee: YOUR ENERGY SYSTEMS, LLCInventor: Frederick Timothy Guilford
-
Publication number: 20170281714Abstract: In the setting of chronic infection with a pathogen, the immune system must adapt to the ongoing presence of inflammatory responses driven by the pathogen in order to control the replication of the infecting agent at an acceptable level while limiting immune-mediated damage (immunopathology) (1). A complex interaction is required to accomplish this using a balance of immune related cytokines to stimulate and control the immune response. A particular formulation of reduced glutathione of high concentration in a liposome is proposed. In cooperation with the immune system, the liposomally formulated reduced glutathione according to the invention surprisingly achieves the balance between over-reduction of IL-10 and its necessary bodily function and signaling.Type: ApplicationFiled: September 28, 2015Publication date: October 5, 2017Applicants: Your Energy Systems, LLC, Western University of Health SciencesInventors: Frederick Timothy Guilford, Vishwanath Venketaraman
-
Publication number: 20170000841Abstract: The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on Klebsiella pneumonia cultures in vitro, and in vivo as demonstrated by efficacy in reducing by large multiples the presence of cultures of Klebsiella in rats in animal tests. Further, because the liposomal glutathione bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more resistant strains to antibiotic treatment is downgraded.Type: ApplicationFiled: August 19, 2016Publication date: January 5, 2017Applicants: Emory University, YOUR ENERGY SYSTEMS, LLC, Children's Healthcare of Atlanta, Inc.Inventors: Lou Ann Brown, Frederick Timothy Guilford
-
Patent number: 9421238Abstract: The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on Klebsiella pneumonia cultures in vitro, and in vivo as demonstrated by efficacy in reducing by large multiples the presence of cultures of Klebsiella in rats in animal tests. Further, because the liposomal glutathione bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more resistant strains to antibiotic treatment is downgraded.Type: GrantFiled: February 14, 2014Date of Patent: August 23, 2016Assignees: YOUR ENERGY SYSTEMS, LLC, EMORY UNIVERSITY, CHILDREN'S HALTHCARE OF ATLANTA, INC.Inventors: Lou Ann Brown, Frederick Timothy Guilford
-
TREATMENT OF MULTIPLE EVOLVING BACTERIAL RESISTANCE DISEASES WITH LIPOSOMALLY FORMULATED GLUTATHIONE
Publication number: 20160158308Abstract: The invention proposes routine treatment of patients, particularly those admitted to an ICU, with Vitamin D and liposomal glutathione for prophylaxis and treatment against Group B Streptococcus and Carbapenem-resistant enterobacteriaceae, and biomarkers to measure effectiveness of treatment. Further, because the method of treatment bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more antibiotic- and/or carbapenem resistant strains is downgraded.Type: ApplicationFiled: August 14, 2014Publication date: June 9, 2016Applicants: EMORY UNIVERSITY, CHILDREN'S HEALTHCARE OF ATLANTA, INC., YOUR ENERGY SYSTEMS, LLCInventors: Lou Ann Brown, Frederick Timothy Guilford -
Publication number: 20150374626Abstract: The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on Klebsiella pneumonia cultures in vitro, and in vivo as demonstrated by efficacy in reducing by large multiples the presence of cultures of Klebsiella in rats in animal tests. Further, because the liposomal glutathione bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more resistant strains to antibiotic treatment is downgraded.Type: ApplicationFiled: March 15, 2013Publication date: December 31, 2015Applicant: YOUR ENERGY SYSTEMS, LLCInventor: Frederick Timothy Guilford
-
Publication number: 20150366933Abstract: The composition of the invention, liposomal glutathione, has been recently shown to have utility for having an antibiotic like effect on Klebsiella pneumonia cultures in vitro, and in vivo as demonstrated by efficacy in reducing by large multiples the presence of cultures of Klebsiella in rats in animal tests. Further, because the liposomal glutathione bolsters body defenses as well as appearing to have direct killing action, the propensity to create more and more resistant strains to antibiotic treatment is downgraded.Type: ApplicationFiled: February 14, 2014Publication date: December 24, 2015Applicants: Emory University, YOUR ENERGY SYSTEMS, LLC, Children's Healthcare of Atlanta, Inc.Inventors: Lou Ann Brown, Frederick Timothy Guilford
-
Publication number: 20140193485Abstract: The invention proposes the combination of reduced glutathione in a liposome (liposomal reduced glutathione) with a specified concentration of reduced glutathione within the liposome for the oral administration of a therapeutically effective amount to ameliorate the progression of vascular disease, including atherosclerosis, diabetes, hypertension, narrowing of arteries leading to decreased blood flow, ischemic events, and the formation of blood clots, abnormal platelet aggregation, and thrombotic events, by reducing the amount and effect of oxidized cholesterol, oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with ACE inhibitors in order to improve the effect of lowering not only cholesterol but also the oxidized cholesterol as well as oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with lisinopril in particular.Type: ApplicationFiled: February 5, 2014Publication date: July 10, 2014Applicant: YOUR ENERGY SYSTEMS, LLCInventor: Frederick Timothy Guilford
-
Publication number: 20140141071Abstract: The invention proposes the sure of reduced glutathione in a liposome (liposomal reduced glutathione) for the oral administration of a therapeutically effective amount to ameliorate the progression of vascular disease, including atherosclerosis, diabetes, hypertension, narrowing of arteries leading to decreased blood flow, ischemic events, and the formation of blood clots, abnormal platelet aggregation, and thrombotic events, by reducing the amount and effect of oxidized cholesterol, oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with statin drugs to improve the effect of lowering not only cholesterol but also the oxidized cholesterol as well as oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with CoQ10 as a therapy for vascular disease and management of side effects of statin therapy.Type: ApplicationFiled: January 27, 2014Publication date: May 22, 2014Applicant: YOUR ENERGY SYSTEMS, LLCInventor: Frederick Timothy Guilford
-
Patent number: 8679530Abstract: The invention proposes the sure of reduced glutathione in a liposome (liposomal reduced glutathione) for the oral administration of a therapeutically effective amount to ameliorate the progression of vascular disease, including atherosclerosis, diabetes, hypertension, narrowing of arteries leading to decreased blood flow, ischemic events, and the formation of blood clots, abnormal platelet aggregation, and thrombotic events, by reducing the amount and effect of oxidized cholesterol, oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with statin drugs to improve the effect of lowering not only cholesterol but also the oxidized cholesterol as well as oxidized HDL and oxidized LDL. The invention also proposes combining liposomal encapsulated glutathione with CoQ10 as a therapy for vascular disease and management of side effects of statin therapy.Type: GrantFiled: October 26, 2006Date of Patent: March 25, 2014Assignee: Your Energy Systems, LLCInventors: F. Timothy Guilford, Brooke Schumm, III
-
Publication number: 20130129815Abstract: The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation in a gel cap. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related to glutathione deficiency such as Parkinson's disease and cystic fibrosis. Compounds enhancing the effect of the liposomal glutathione are contemplated such as Selenium, EDTA, carbidopa, and levodopa.Type: ApplicationFiled: December 31, 2012Publication date: May 23, 2013Applicants: YOUR ENERGY SYSTEMS, LLCInventors: Your Energy Systems, LLC, Frederick Timothy Guilford, Brian C. Keller
-
Patent number: 8349359Abstract: The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related to glutathione deficiency such as Parkinson's disease and cystic fibrosis. Compounds enhancing the effect of the liposomal glutathione are contemplated such as Selenium, EDTA, carbidopa, and levodopa.Type: GrantFiled: November 6, 2005Date of Patent: January 8, 2013Assignee: Your Energy Systems, LLCInventors: F. Timothy Guilford, Brian Charles Keller
-
Publication number: 20120219616Abstract: The invention enables management of mammalian disease related to decreased energy production in the mitochondria by a combination of liposomal reduced glutathione and 1-arginine. For individuals whose inability to lose weight is related to inefficiency of the biochemical pathways facilitating mitochondrial function and energy production, the invention proposes to assist in weight loss by improving the inefficient production of energy by the respiratory transport chain of mitochondria. The invention is useful for the management of the metabolic syndrome, a group of metabolic factors associated with an increased risk of vascular disease problems. The invention is also useful for the resolution of fatigue that accompanies both weight gain and illnesses. The ability of the invention to increase the production of the biochemical agmatine in the central nervous system as well as generally in the body is part of the benefit of the combination of liposomal reduced glutathione and 1-arginine.Type: ApplicationFiled: February 8, 2012Publication date: August 30, 2012Applicant: YOUR ENERGY SYSTEMS, LLCInventors: F. Timothy Guilford, Brian C. Keller
-
Patent number: 8252325Abstract: The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related to glutathione deficiency such as Parkinson's disease and cystic fibrosis. Compounds enhancing the effect of the liposomal glutathione are contemplated such as Selenium, EDTA, carbidopa, and levodopa.Type: GrantFiled: February 15, 2012Date of Patent: August 28, 2012Assignee: Your Energy Systems, LLCInventors: F. Timothy Guilford, Brian C. Keller
-
Patent number: 8147869Abstract: The invention is a composition administrable orally to provide systemic glutathione (reduced) and a method for providing systemic glutathione by oral administration of glutathione (reduced) in a liposome encapsulation. The administration of a therapeutically effective amount of oral liposomal glutathione (reduced) results in improvement of symptoms in disease states related to glutathione deficiency such as Parkinson's disease and cystic fibrosis. Compounds enhancing the effect of the liposomal glutathione are contemplated such as Selenium, EDTA, carbidopa, and levodopa.Type: GrantFiled: August 31, 2011Date of Patent: April 3, 2012Assignee: Your Energy Systems, LLCInventors: F. Timothy Guilford, Brian C. Keller
-
Patent number: 8114913Abstract: The invention is for the combination and related methods of N-acetyl-cysteine oral, inhaled, or intravenous, or glutathione inhaled or intravenous, generally in combination with antibiotic and/or antiviral therapy to ameliorate the toxic effects of infection with materials used in Bioterror incidents such as Bacillus anthracis and smallpox virus, and alternatively, upon exposure to radiation, during testing, and vaccination, as treatment prior to treatment with antibiotic or antiviral therapy to ameliorate the toxic effects of infection and exposure with these organisms.Type: GrantFiled: June 18, 2009Date of Patent: February 14, 2012Assignee: Your Energy Systems, LLCInventors: F. Timothy Guilford, Brooke Schumm, III